

ELECTION AND REMARKS

In response to the requirement that a single species of PKC (*e.g.*, alpha or beta) be elected in the claimed invention, Applicants elect alpha. Claims 1-2, 9-44 and 56-61 read on the elected species.

In response to the requirement that a single agent be further elected in the claimed invention of the above-elected species, Applicants elect Group D (inhibitor of PKC). Claims 1-2, 9, 22-26, 28, 30-44, and 59-61 read on the elected species.

In response to the requirement that if D is elected, Applicants are then required to further elect an ultimate species of “inhibitor” recited in claims 22-26 and 40-43. Accordingly, Applicants elect the species set forth in claim 25 “wherein said inhibitor . . . changes the phosphorylation state of protein kinase C-alpha.” Claims 1, 2, 9, 25, 26, 28, 30-44, and 59-61 read on this further elected species. If the Examiner requires that a species of the inhibitor of claim 25 be further elected, Applicants elect tocopherol. Claims 1, 2, 9, 25, 26, 28, 30-44, and 59-61 read on this further elected species.


The above-elections are made without traverse.

Applicants now believe that they have fully responded to the Restriction/Election Requirements issued by the Office, and that the claims are in condition for examination. Early and favorable action on the merits is respectfully requested.

Applicants: Jan MENNE *et al.*
Application No. 10/528,806

No fee is believed to be required. However, if a fee is determined to be due, please charge the amount to our Deposit Account No. 22-0261. A Fee Transmittal is attached for this purpose.

Respectfully submitted,



Date: July 2, 2007

Steven R. Ludwig, Ph.D.
Registration No. 36,203
VENABLE LLP
P.O. Box 34385
Washington, D.C. 20043-9998
Telephone: (202) 344-4000
Telefax : (202) 344-8300

SRL/SJB
DCDocs2/873051